Liquidia (NASDAQ:LQDA) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a report released on Thursday morning,Benzinga reports. They currently have a $19.00 price objective on the stock.

A number of other analysts also recently issued reports on the stock. Lifesci Capital assumed coverage on shares of Liquidia in a report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. Scotiabank assumed coverage on Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target for the company. HC Wainwright reissued a “buy” rating and issued a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Finally, Wells Fargo & Company started coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 target price for the company. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $25.38.

Liquidia Trading Up 0.5 %

Shares of NASDAQ:LQDA opened at $12.46 on Thursday. The company has a market capitalization of $1.05 billion, a PE ratio of -7.64 and a beta of 0.23. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99. The business has a 50 day moving average of $11.10 and a two-hundred day moving average of $11.03.

Insider Buying and Selling

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of the business’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $11.19, for a total transaction of $28,265.94. Following the transaction, the insider now owns 204,857 shares of the company’s stock, valued at approximately $2,292,349.83. The trade was a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $28,619.36. Following the completion of the sale, the general counsel now directly owns 486,048 shares of the company’s stock, valued at $5,399,993.28. This trade represents a 0.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,007 shares of company stock worth $245,780. 30.10% of the stock is owned by insiders.

Institutional Trading of Liquidia

Hedge funds have recently made changes to their positions in the company. Quest Partners LLC acquired a new position in Liquidia in the second quarter valued at approximately $27,000. Clear Harbor Asset Management LLC acquired a new position in shares of Liquidia in the 3rd quarter valued at $100,000. Signaturefd LLC grew its holdings in shares of Liquidia by 38,400.0% during the 3rd quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after purchasing an additional 9,984 shares during the period. Ballentine Partners LLC acquired a new stake in shares of Liquidia during the 3rd quarter worth about $110,000. Finally, Whitcomb & Hess Inc. raised its holdings in Liquidia by 10.2% in the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after buying an additional 1,074 shares during the period. Hedge funds and other institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).